Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 | O43614 | 12/20 | 1.00 |
| ▸ | RET | P07949 | 4/20 | 0.40 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.35 |
| ▸ | DPP4 | P27487 | 1/20 | 0.35 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.34 |
| ▸ | CBLB | Q13191 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27181021 | 1.00 | HCRTR2 (1.00) | HCRTR2RETTGFBR1DPP4MCHR1 | |
| SCHEMBL24529170 | 1.00 | HCRTR2 (1.00) | HCRTR2RETTGFBR1DPP4MCHR1 | |
| SCHEMBL27180349 | 0.85 | HCRTR2 (0.73) | HCRTR2 | |
| SCHEMBL24529473 | 0.85 | HCRTR2 (0.73) | HCRTR2 | |
| SCHEMBL27180350 | 0.85 | HCRTR2 (0.73) | HCRTR2 | |
| SCHEMBL24529173 | 0.84 | HCRTR2 (0.72) | HCRTR2RETTGFBR1MCHR1 | |
| SCHEMBL24529302 | 0.81 | HCRTR2 (0.68) | HCRTR2 | |
| SCHEMBL27181328 | 0.81 | HCRTR2 (0.68) | HCRTR2 | |
| SCHEMBL24529299 | 0.79 | HCRTR2 (0.66) | HCRTR2RETCBLB | |
| SCHEMBL27181350 | 0.79 | HCRTR2 (0.66) | HCRTR2RETCBLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4262788-B1 | UREA OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME LLC (US) | 2026-01-21 | — | — | EP | claimed |
| US-20240101555-A1 | UREA OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME LLC (US) | 2024-03-28 | — | — | US | claimed |
| EP-4262788-B1 | UREA OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME LLC (US) | 2026-01-21 | — | — | EP | disclosed |
| US-20240101555-A1 | UREA OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME LLC (US) | 2024-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240101555-A1 | UREA OREXIN RECEPTOR AGONISTS | HCRTR1, HCRTR2, UTS2R | HCRTR2 2/4885RET 335/4885TGFBR1 2179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.